These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31030578)

  • 41. Desloratadine and depression, a drug safety signal based on worldwide spontaneous reporting of side effects.
    Boer J; Ederveen E; Grundmark B
    Ups J Med Sci; 2018 Sep; 123(3):174-178. PubMed ID: 30084285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety reporting through a comprehensive and pragmatic pharmcovigilance process for India and emerging markets: an industry perspective.
    Swamy S; Mourya M; Kadhe G; Mane A; Sawant S
    Expert Opin Drug Saf; 2015; 14(9):1409-20. PubMed ID: 26292785
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.
    Tanti A; Micallef B; Serracino-Inglott A; Borg JJ
    Expert Opin Drug Saf; 2017 Jan; 16(1):65-76. PubMed ID: 27732110
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An Evaluation of Indian Consumers' Reporting of Suspected Adverse Drug Reactions with a Designated Reporting Form.
    Rehan HS; Sah R; Gupta A; Nagar P
    Curr Drug Saf; 2017; 12(1):51-56. PubMed ID: 27188794
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Governance of nutrivigilance in the Netherlands: Reporting adverse events of non-registered products.
    de Boer A; Geboers L; van de Koppel S; van Hunsel F
    Health Policy; 2022 Aug; 126(8):731-737. PubMed ID: 35643570
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Feedback for patients reporting adverse drug reactions; satisfaction and expectations.
    Rolfes L; van Hunsel F; van Grootheest K; van Puijenbroek E
    Expert Opin Drug Saf; 2015 May; 14(5):625-32. PubMed ID: 25766456
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacovigilance Skills, Knowledge and Attitudes in our Future Doctors - A Nationwide Study in the Netherlands.
    Schutte T; Tichelaar J; Reumerman MO; van Eekeren R; Rissmann R; Kramers C; Richir MC; van Puijenbroek EP; van Agtmael MA;
    Basic Clin Pharmacol Toxicol; 2017 May; 120(5):475-481. PubMed ID: 27883270
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patients' Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana.
    Sabblah GT; Darko DM; Mogtari H; Härmark L; van Puijenbroek E
    Drug Saf; 2017 Oct; 40(10):911-921. PubMed ID: 28653291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The validity and reliability of a signal impact assessment tool.
    Rolfes L; Kolfschoten J; van Hunsel F; van Puijenbroek E
    Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):815-9. PubMed ID: 27193557
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current state of biologic pharmacovigilance in the European Union: improvements are needed.
    Felix T; Jordan JB; Akers C; Patel B; Drago D
    Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hearing impairment associated with oral terbinafine use: a case series and case/non-case analysis in the Netherlands Pharmacovigilance Centre Lareb database and VigiBase™.
    Scholl JH; van Puijenbroek EP
    Drug Saf; 2012 Aug; 35(8):685-91. PubMed ID: 22762134
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions.
    van Puijenbroek E; Diemont W; van Grootheest K
    Drug Saf; 2003; 26(5):293-301. PubMed ID: 12650632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Public confidence in ADR identification and their views on ADRreporting: mixed methods study.
    Jarernsiripornkul N; Patsuree A; Krska J
    Eur J Clin Pharmacol; 2017 Feb; 73(2):223-231. PubMed ID: 27837337
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacoepidemiology and its input to pharmacovigilance.
    Faillie JL; Montastruc F; Montastruc JL; Pariente A
    Therapie; 2016 Apr; 71(2):211-6. PubMed ID: 27080840
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The quality of spontaneous adverse drug reaction reports from the pharmacovigilance centre in western China.
    Niu R; Xiang Y; Wu T; Zhang Z; Chen Y; Feng B
    Expert Opin Drug Saf; 2019 Jan; 18(1):51-58. PubMed ID: 30574811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Evaluation of a new pharmacovigilance tool: Simplified online reporting for general practitioners].
    Humbert X; Chrétien B; Sassier M; Coquerel A; Alexandre J; Fedrizzi S
    Sante Publique; 2018; 30(2):225-232. PubMed ID: 30148310
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial.
    Defer G; Le Caignec F; Fedrizzi S; Montastruc F; Chevanne D; Parienti JJ; Peyro-Saint-Paul L
    Trials; 2018 Mar; 19(1):174. PubMed ID: 29523169
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).
    Thiessard F; Roux E; Miremont-Salamé G; Fourrier-Réglat A; Haramburu F; Tubert-Bitter P; Bégaud B
    Drug Saf; 2005; 28(8):731-40. PubMed ID: 16048358
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects.
    van Eekeren R; Rolfes L; Koster AS; Magro L; Parthasarathi G; Al Ramimmy H; Schutte T; Tanaka D; van Puijenbroek E; Härmark L
    Drug Saf; 2018 Nov; 41(11):1003-1011. PubMed ID: 29949100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Good Signal Detection Practices: Evidence from IMI PROTECT.
    Wisniewski AF; Bate A; Bousquet C; Brueckner A; Candore G; Juhlin K; Macia-Martinez MA; Manlik K; Quarcoo N; Seabroke S; Slattery J; Southworth H; Thakrar B; Tregunno P; Van Holle L; Kayser M; Norén GN
    Drug Saf; 2016 Jun; 39(6):469-90. PubMed ID: 26951233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.